Bile duct cancer is a highly aggressive malignancy wherein early diagnosis is difficult and few treatment options are available. ) is reported to be related with survival in patients with gastrointestinal cancers; however, the regulatory mechanism of miR-31 and association between miR-31 expression and survival in patients with bile duct cancer cases have not been established. Thus, we evaluated miR-31 expression in bile duct cancer tissues and assessed its relationship with prognosis. Additionally, we examined the effects of several cytokines on miR-31 expression. The study included 81 samples of bile duct cancer tissues. MiR-31 expression in bile duct cancer cells was significantly higher than that in normal bile duct epithelial cells (P = 0.038). There were no significant associations between miR-31 expression and clinical or pathological characteristics, except for tumour size (P = 0.012). In Kaplan-Meier analysis, high miR-31 expression was significantly associated with shorter survival (log-rank test, P = 0.0082). In multivariate Cox regression analysis, high miR-31 expression was significantly associated with prognosis (P = 0.043), independent of clinical or pathological features. Interleukin-6 (IL-6) significantly promoted miR-31 expression and cell proliferation in a dose-dependent manner, and the inhibition of STAT-3 signalling significantly suppressed miR-31 expression and cell proliferation. In conclusion, high expression was significantly associated with poor prognosis in bile duct cancer patients. The IL-6-STAT-3 signalling regulated bile duct cancer cell proliferation and miR-31 expression. Our findings suggest that miR-31 may be a promising biomarker that reflects IL-6 expression in bile duct cancer tissues and predicts poor prognosis.
Introduction
Bile duct cancer is a highly aggressive malignancy that arises from bile duct epithelial cells. Surgical treatment is considered to be the only curative treatment for a bile duct cancer; however, several patients with bile duct cancer are diagnosed only at an advanced stage because of the difficulty in early diagnosis. In recent years, the overall survival (OS) rate and therapeutic options for bile duct cancer have not improved. Therefore, better understanding of the pathogenesis of bile duct cancers is urgently required (1) (2) (3) .
MicroRNAs are a class of small non-coding RNA molecules that function as post-transcriptional gene regulators, and they have been increasingly recognized as useful biomarkers in various human cancers (4) (5) (6) (7) (8) . A recent study showed that microRNAs can act as both oncogenic and tumour suppressive agents, depending on the genes they regulate (9, 10) . We previously reported the negative association between miR-31 expression in cancer tissues and survival among patients with gastrointestinal cancers, including colorectal and pancreatic cancers (11) (12) (13) . With regard to bile duct cancer, miR-31 is reported to be upregulated in tumour tissues, and it not only promotes cellular proliferation but also inhibits apoptosis (14) (15) (16) . However, no study has reported the association between miR-31 expression and survival among patients with bile duct cancer.
Previous reports have demonstrated that chronic inflammation can affect carcinogenesis and that a large part of the immune system depends on cytokines. Interleukin-6 (IL-6), one of the most common inflammatory cytokines, is produced by diverse cell types and is a crucial mediator of immunity. IL-6 receptors transduce signals via gp130 (also known as IL-6Rβ), which is a shared receptor chain of the IL-6 family and is a strong inducer of signal transducers and activator of transcription 3 (STAT3) activation. IL-6 plays several important roles in cancer progression, and it drives processes, including proliferation, migration and angiogenesis. IL-6-dependent STAT3 signalling is a critical promoter of cancer cell proliferation and survival (17) (18) (19) (20) . In addition, the gene locus of miR-31 has been reported to possess a STAT-3 binding site; therefore, IL-6 was found to induce miR-31 expression in vitro (21, 22) . However, these relationships have not been established in a gastrointestinal cancer model, including a bile duct cancer model. Thus, we evaluated miR-31 expression in bile duct cancer tissues and assessed its relationship with prognosis. Furthermore, we examined the effects of several cytokines on miR-31 expression in bile duct cancer cells to determine whether it could reflect cytokine expression in bile duct cancer tissue.
Materials and methods

Patients and tissue specimens
Formalin-fixed, paraffin-embedded (FFPE) tissues of 81 patients with bile duct cancers [stages I-IV, in accordance with Union according to International Cancer Control (UICC) 7th edition], who underwent surgical treatment at Sapporo Medical University Hospital and Muroran City General Hospital between March 2001 and September 2015, were collected. To avoid selection bias as much as possible, the FFPE tissue specimens were collected consecutively. Bile duct cancer was classified by location as follows: intrahepatic cholangiocarcinoma (n = 16), extrahepatic cholangiocarcinoma (n = 37) and gallbladder cancer (n = 28). Patients were followed until death or December 2015 (whichever was first). Informed consent was obtained from all the patients before specimen collection. This study was approved by the respective institutional review boards of the participating institutions.
RNA extraction from bile duct cancer tissue and qRT-PCR of miR-31
We have collected the bile duct cancer cells and adjacent normal bile duct epithelium cells from FFPE samples of bile duct cancer patients using the MMI Cellcut plus microdissection system (MMI, Eching, Germany).
Total RNA was extracted using miRNeasy FFPE Kit (Qiagen, Valencia, CA). MicroRNA-31 (miR-31)-5p expression was analysed by quantitative reverse transcription-PCR (qRT-PCR) using TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) and TaqMan micro-RNA Assays (Applied Biosystems) as described previously (11) . U6 snRNA (RNU6B; Applied Biosystems) served as an endogenous control. MiR-31 expression was calculated using the equation 2 −ΔC T , where ΔC T = (C T miR-31 − C T U6). To calculate the relative expression of miR-31 in each bile duct cancer, 2 −ΔC T of cancer tissue was divided by 2 −ΔC T of normal tissue, as described previously (11) .
Bile duct cancer cell lines and induction of miR-31 expression
In this study, we used three bile duct cancer cell lines (HuCCT-1, TFK-1 and HuH-28). HuCCT-1 was provided by HSRRB, TFK-1 was provided by RIKEN BRC and HuH-28 was provided by JCRB. Each cell line was validated by analysis of STRs (GenePrint® 10 System, Promega, Barcelona, Spain). Cells were grown in RPMI-1640 (Sigma-Aldrich, St. Louis, MI) supplemented with heat-inactivated 10% FBS (Sigma-Aldrich) in an atmosphere of 5% CO 2 at 37°C. Cells showing 70% confluency were stimulated with 0, 20 and 50 ngml −1 of IL-6 (PEPROTECH, Rock Hill, NJ), TNF-α (PEPROTECH), IL-1β (PEPROTECH), IL-17A (PEPROTECH) and IL-10 (PEPROTECH). Cells were harvested for qRT-PCR 24 h after stimulation. To verify the involvement of STAT-3, each cell line was also treated with S3I-201 (Sigma-Aldrich) for 24 h at final concentration of 30 or 300 μM. In the study involving S3I-201, each sample contained an equal amount of DMSO to exclude the possibility of the effects of DMSO.
Western blotting
To confirm the effect of S3I-201, we harvested cells after 24 h of treatment with S3I-201 at final concentration of 30, 100 or 300 μM. Cultured bile duct cancer cells were lysed in Cell lytic-M (Sigma-Aldrich) containing PhosSTOP (Sigma-Aldrich) and Complete mini (Sigma-Aldrich). Antibodies used for western blotting were as follows: rabbit anti-STAT3 (phosphor Y705) antibody (Abcam, Cambridge, UK), rabbit anti-STAT3 antibody-HRP conjugate (Abcam) and antiactin antibody (Wako, Osaka, Japan). Data were analysed using LAS-3000 (FUJIFILM, Tokyo, Japan).
RNA isolation from bile duct cancer cell lines and qRT-PCR
Total RNA was extracted using TRI REAGENT (Molecular Research Center, Cincinnati, OH) and Direct-zol RNA mini-prep plus kit (Zymo Research, Orange, CA). MiR-31-5p expression was analysed by qRT-PCR using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) and TaqMan microRNA Assay (Applied Biosystems). U6 snRNA (RNU6B; Applied Biosystems) was used as an endogenous control. For the analysis of suppressor of cytokine signalling 3 (SOCS3) and RAS p21 GTPaseactivating protein (RASA-1) expression, complementary DNA was synthesized using the Super script VILO cDNA Synthesis Kit and Master Mix (Thermo Fisher, Waltham, MA). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression was used to normalize variance. qRT-PCR was performed using the PowerUp SYBR green master mix (Thermo Fisher) and 7500 Real-Time PCR system (Applied Biosystems). All the genes were assessed in triplicates. The following primer sequences were used: GAPDH, forward primer, 5′-CAACAGCCTCAAGATCATCAG-3′, reverse primer, 5′-CTGTGGTCATGAGTCCTTCC-3′; IL-6, forward primer, 5′-CAGTTCCTGCAG AAAAAGGCAA-3′, reverse primer, 5′-AGCTGCGCAGAATGAGATGA-3′; IL-6R, forward primer, 5′-CCCATGCAGGCACTTACTAC-3′, reverse primer, 5′-TCCAGCAACCAGGAATGTGG-3′; SOCS3, forward primer, 5′-CGGAGACTTCGATTCGGGAC-3′, reverse primer, 5′-GCTGGTACTCG CTCTTGGAG-3′; RASA-1, forward primer, 5′-TTGGAGCTAAGGAGCCC TACA-3′, reverse primer, 5′-GAGCCACGCAAATCTCATGC-3′.
Assays for proliferation
The proliferation of bile duct cancer cells stimulated with IL-6 was analysed by measuring the uptake of WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt] in a colorimetric assay (CCK-8 assay, Dojindo, Tokyo, Japan).
Briefly, bile duct cancer cells showing 70% confluency were dispensed into 96-well plates at a density of 3 × 10 3 cells per well with RPMI-1640 containing 2% FBS and 0, 20 and 50 ng ml −1 of IL-6. After incubation for 0, 48 and 96 h, 10 µl of CCK-8 or medium was added to each well, and the plate was then incubated for 2 h at 37°C, and absorbance was measured at 450 nm on Multiskan FC (Thermo Fisher) using a CCK-8 kit as per manufacturer's instructions.
MiRNA transient transfection and gene expression microarray analysis
TFK-1 and HuH-28 cells were cultured as described above. Cells at 70% confluency were transfected with 20 pmol hsa-miR-31-5p mirVana miRNA mimic (Thermo Fisher) or 20 pmol mirVana miRNA mimic negative control (Thermo Fisher) using Lipofectamine RNAiMAX Transfection Reagent (Thermo Fisher). Total RNA was extracted 48 h after transfection. One-color microarray-based gene expression array analysis was then performed according to the manufacturer's instructions (Agilent Technologies, Santa Clara, CA). Briefly, 100 ng of total RNA was amplified and labelled using the Low-input Quick Amp Labelling kit, onecolor (Agilent Technologies). The synthesized cRNA was subsequently hybridized to SurePrint G3 Unrestricted GE 8x60K (G4858A; Agilent Technologies). The microarray experiments were performed in duplicate, and data were analysed using GeneSpring GX version 13 (Agilent Technologies).
Statistical analysis
JMP (version 10) software programs were used for statistical analyses (SAS Institute, Cary, NC). All P-values were two-sided. Univariate analyses were performed to investigate clinical and pathological characteristics according to miR-31 expression. Chi-square or Fisher's exact test was used for categorical data, while analysis of variance was used to compare the mean patient age and tumour size. Kaplan-Meier method and log-rank test were used to assess the association between miR-31 expression status and patient survival. Additionally, Cox proportional hazards regression models were used to compute the mortality hazard ratio according to miR-31 expression status. The multivariate Cox model included miR-31 expression stratified by tumour size and pathological stage.
Results
MicoroRNA-31 expression in bile duct cancer tissue
We collected and extracted RNA from bile duct cancer cells and adjacent normal bile duct epithelial cells from7 FFPE samples using the MMI Cellcut plus microdissection system (MMI). We calculated miR-31 expression using the equation 2 −ΔCT , where ΔC T = (C T miR-31 − C T U6). MiR-31 expression in bile duct cancer cells was significantly higher than in normal bile duct epithelial cells (paired t-test; P = 0.038; Figure 1a) .
Distribution of miR-31 expression in the 81 bile duct cancer samples was as follows: mean, 2.36; median, 0.13; standard deviation (SD) (Table 1) . We categorized pathological stages into stages I, II, III and IV for further analysis because of the difference in TNM classification according to tumour location.
Association between miR-31 expression and clinical or pathological characteristics in bile duct cancer
bile duct cancer according to miR-31 expression. We observed a significant association between miR-31 expression and tumour size. However, there were no significant associations between miR-31 expression and other clinical or pathological characteristics, including sex, age, tumour location, N factor, M factor, disease stage, preoperative biliary drainage before resection and the preoperative CRP level, except tumour size
MiR-31 expression and patient survival
We assessed the influence of miR-31 expression on clinical outcomes in 81 patients with bile duct cancer (stages I-IV). The median follow-up time for OS was 25.1 months. Kaplan-Meier analysis revealed that survival was significantly shorter in the high miR-31 expression group than in the low miR-31 expression group (log-rank P = 0.0082; Figure 1b) .
Univariate Cox regression analysis for OS revealed significantly shorter survival in the high miR-31 expression group than in the low miR-31 expression group (hazard ratio: 2.08; 95% confidence interval: 1.22-4.19; P = 0.0089). Multivariate Cox regression analysis adjusted for pathological stage and tumour size revealed that survival was significantly shorter in the high miR-31 expression group than in the low miR-31 expression group (hazard ratio: 2.08; 95% confidence interval: 1.02-4.28; P = 0.043; Supplementary Table 1) . To identify key cytokines for the induction of miR-31, we stimulated the bile duct cancer cell lines with IL-1β, IL-6, IL-10, IL-17A and TNF-α. We confirmed that the receptor of these cytokines was expressed in the bile duct cancer cell lines (data not shown). Among the cytokines, only IL-6 significantly enhanced miR-31 expression in both bile duct cancer cell lines, whereas IL-10, TNF-α, IL-1β and IL-17A did not enhance miR-31 expression (Figure 2a-e) . We also examined the expression of SOCS3 00to confirm whether miR-31 expression was regulated through the IL-6-STAT-3 signalling pathway. SOCS3 expression was significantly upregulated after IL-6 treatment of the cell lines (Figure 2f ). Next, we examined miR-31 expression after treatment with S3I-201, which inhibits STAT-3 phosphorylation, activation, dimerization and DNA-binding. Western blotting showed that S3I-201 significantly inhibited STAT-3 phosphorylation (Supplementary Figure 2 , available at Carcinogenesis Online). Quantitative PCR revealed that STAT-3 inhibition significantly suppressed miR-31 expression in a dose-dependent manner (Figure 3a and b) . These results suggested that the IL-6-STAT-3 pathway induced miR-31 expression.
Induction of miR-31 in bile duct cancer
Functional analysis of IL-6 addition to bile duct cancer cell lines
In the proliferation assay, IL-6 treatment significantly increased cell proliferation of bile duct cancer cell lines compared with control (Figure 4a and b) . S3I-201 treatment significantly inhibited the proliferation of each cell line treated with IL-6 (Figure 4c  and d) . Taken together, these data indicated that the IL-6-STAT-3 pathway was obviously associated with tumorigenesis in bile duct cancer.
Gene expression microarray analysis after transient miR-31 transfection
To identify the downstream targets of miR-31 in bile duct cancer cells, we performed gene expression microarray analysis with TFK-1 and HuH-28 cells transfected with the miR-31 mimic or negative control. The microarray analysis demonstrated that 617 probe sets (corresponding to 569 unique genes) were downregulated and 460 probe sets (corresponding to 415 unique genes) were upregulated by the miR-31 mimic in bile duct cancer cells (Figure 5a ). The expressions of RASA-1 and Axin-1, which were previously reported as miR-31 target genes, were downregulated (Figure 5b) . A validation study using real-time PCR revealed that transient transfection of the miR-31 mimic significantly downregulated RASA-1 expression in bile duct cancer cells (Figure 5c ). Pathway analysis revealed that genes associated with MAPK signalling and Wnt signalling were significantly enriched among the genes downregulated (>1.0-fold) by transient miR-31 mimic transfection (Figure 5d ).
Discussion
This study demonstrated that miR-31 was highly expressed in bile duct cancer cells and that high miR-31 expression was significantly associated with shorter survival, independent of clinicopathological features. Additionally, IL-6 treatment in bile duct cancer cell lines promoted miR-31 expression and cell proliferation in a dose-dependent manner, and the inhibition of the STAT-3 signalling pathway significantly suppressed miR-31 expression and cell proliferation. Therefore, our data suggested that miR-31, which is regulated by the IL-6-STAT-3 signalling pathway, could be a prognostic biomarker of bile duct cancer.
The miR-31 gene is located at chromosome 9p21.3 and is reportedly deregulated in various human cancers (23) (24) (25) . Using microRNA array analysis, we previously reported that miR-31 expression was significantly upregulated in BRAF-mutated colorectal cancer when compared with wild-type colorectal cancer Percentage (%) indicates the proportion of cases with a specific clinicopathological feature within a given category of miR-31. P-values were calculated by analysis of variance for age, tumour size and preoperative CRP and by a chi-square test or Fisher's exact test for all other variables. *P < 0.05. (11) . Moreover, we found associations between miR-31 expression and poor prognosis in colorectal cancer and pancreatic ductal adenocarcinoma (12, 13) . Using a bile duct cancer database in the present study, we revealed that high miR-31 expression was significantly associated with poor prognosis, as in colorectal cancer and pancreatic ductal adenocarcinoma. Interestingly, a positive correlation between high miR-31 expression and tumour size in bile duct cancers was also observed. Previous reports demonstrated that miR-31 promoted cell proliferation in breast cancer (25) and colorectal cancer (26) . Especially in bile duct cancer, miR-31 has been reported to promote cell proliferation by targeting RASA1 in vitro (15) . In this study, we found that the gene expressions of RASA-1 and the Wnt signal antagonist Axin-1 were downregulated in miR-31 mimic-transfected bile duct cancer cells. Additionally, the results of pathway analysis revealed that the genes associated with MAPK signalling and Wnt signalling were significantly enriched among the 569 genes downregulated. Consistent with the findings of previous reports, our data strongly suggest that high miR-31 expression is involved in tumour growth.
Immune response is a series of events comprising recognition of pathogens or tissue damage, which involves cells and chemical mediators such as cytokines. Inflammation is a part of the immune response to eliminate the initial cause of cell injury and initiate tissue repair (27) . However, it is widely known that chronic inflammation can increase the risk of cancer. In bile duct cancer, primary sclerosing cholangitis, which causes chronic inflammation and liver injury, is an established risk factor (2, 28) . Recent studies revealed that sustained inflammation with hepatitis C virus and hepatitis B virus could result in the development of bile duct cancer (29) (30) (31) . Thus, several inflammatory cytokines participate in both the initiation and progression of cancer (32) . Recently, it has been considered that several microRNAs, such as miR-31, have significant roles in immune regulation (33, 34) . Furthermore, previous studies demonstrated that the transcription factors NFκB and STAT-3 could potentially bind to the promoter region of the miR-31 gene (21, 22) . In this regard, we investigated the cytokines that could affect miR-31 induction. We found that IL-6 treatment significantly increased miR-31 expression in bile duct cancer cell lines.
Generally, IL-6 is known as a proinflammatory cytokine, and it plays an important role in the cancer microenvironment (35) . IL-6 promotes cancer cell proliferation, invasion and angiogenesis in many types of cancers (36) (37) (38) (39) (40) (41) (42) . With regard to IL-6 involvement in the differentiation of bile duct cancer, it has been reported that IL-6 could induce metastasis in bile duct cancer through the acquisition of epithelial-mesenchymal transition (18) .
In this study, we found that the bile duct cancer cell lines HuCCT-1 and TFK-1 endogenously expressed IL-6 and IL-6 receptor (Supplementary Figure 1b and c, available at Carcinogenesis Online). These findings suggested that the IL-6-STAT-3 feed-forward loop might be involved in driving the tumorigenesis of bile duct cancers (35, 43) . Additionally, it has been reported that not only autocrine but also extrinsic IL-6 stimulation can cause a further increase in cell proliferation. Unfortunately, our data could not prove whether IL-6 derived from cancer cells was mainly involved in bile duct cancer growth when compared with that derived from immune cells. However, considering the present findings and the results of previous reports, the miR-31-IL-6 axis may play a crucial role in bile duct cancer growth.
The in vitro study showed that S3I-201 treatment inhibited even innately activated IL-6-STAT-3 signalling, resulting in dramatic decrease in miR-31 expression and cell proliferation. SOCS3 is a protein that negatively regulates IL-6 receptor gp130 expression in response to IL-6 activation, which consequently prevents the continuous activation of STAT-3. To confirm whether IL-6-STAT-3 signalling certainly regulates miR-31 expression in bile duct cancer, we examined SOCS3 expression. As a result, IL-6 treatment in bile duct cancer cell lines significantly upregulated SOCS3 expression. Thus, our findings suggested that miR-31 is an independent prognostic factor that reflects IL-6-STAT-3 signalling in the cancer microenvironment, and miR-31 has an oncogenic role.
The present study has some limitations. Our study was limited by its cross-sectional design and bias potential (i.e. selection bias) that could have confounded the results. Nevertheless, our multivariate regression analysis was adjusted for potential clinical and pathological confounders. Although a further study is needed to confirm our results, this study is an interesting first step toward the improved understanding and diagnosis of bile duct cancer.
In conclusion, high miR-31 expression was observed in bile duct cancer tissue, and which was independently associated with poor prognosis. There was a significant association between the IL-6-STAT-3 signalling pathway and both the proliferation of bile duct cancer cells and the expression of miR-31. Our findings strongly suggest that miR-31 could be a promising biomarker for predicting the prognosis of patients with bile duct cancer.
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